Physician profile
Andrew I Jun
NPI 1841270717
$3,891.10
in general payments reported to CMS, 2019-2025
29 companies · $892 in 2025
The $892 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $643 · 2021: $490 · 2022: $406 · 2023: $371 · 2024: $431 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.25 |
| Education | $176.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $564.93 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $537.59 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Janssen Biotech, INC. | $442.24 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $352.52 | 2021-2025 | Dupixent, Libtayo |
| Surgenex LLC | $256.77 | 2025 | Surgraft, Surmatrix, Pellograft |
| Vyne Pharmaceuticals INC. | $229.93 | 2020-2021 | |
| Leo Pharma INC. | $171.31 | 2019-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $159.48 | 2021-2022 | |
| Aerin Medical INC. | $156.64 | 2019 | |
| Abbvie INC. | $137.03 | 2020-2025 | |
| Genentech USA, INC. | $122.32 | 2019-2024 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $121.89 | 2024 | Sotyktu |
| Mimedx Group, INC. | $96.35 | 2024-2025 | |
| Allergan, INC. | $91.01 | 2019-2022 | |
| Amgen INC. | $72.65 | 2024-2025 | Otezla, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $57.90 | 2025 | Bimzelx |
| Acclarent, INC | $51.74 | 2019 | |
| Lilly USA, LLC | $36.38 | 2022-2023 | Olumiant, Taltz |
| Incyte Corporation | $34.32 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.99 | 2019-2020 | |
| Epi Health, LLC | $24.70 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $21.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.17 | 2021 | |
| Mayne Pharma Commercial LLC | $19.28 | 2020 | |
| Almirall LLC | $19.27 | 2019 | |
| Biofrontera INC. | $18.81 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $17.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.62 | 2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Jun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.